Peter Loftus

1 week ago | wsj.com | Peter Loftus

Eli Lilly Chief Executive David Ricks (Annabelle Gordon/Bloomberg News)The head of drugmaker Eli Lilly, which sells the popular weight-loss drug Zepbound, urged the Trump administration to ease up on its tariff rollout because it could hurt Lilly’s business and the broader pharmaceutical industry. “We don’t believe tariffs are the right mechanism” to bolster U.S. drug manufacturing, Lilly Chief Executive David Ricks said on a conference call with analysts Thursday.

2 weeks ago | wsj.com | Peter Loftus

President Trump's tariffs are eating into profits at GE Healthcare, the large maker of imaging and other medical equipment that was spun out of General Electric in 2023. GE Healthcare reduced its forecast of full-year 2025 adjusted earnings by about 15% from its prior view, with U.S. and China bilateral tariffs accounting for most of the hit.

3 weeks ago | wsj.com | Peter Loftus

Drugmakers Roche and Regeneron said they will spend billions of dollars to expand U.S. manufacturing, the latest pharmaceutical companies to commit to American production as new and future tariffs loom over medicines made abroad. Roche will invest $50 billion over five years, including in a new factory to make glucose-monitoring devices and a new plant for weight-loss drugs. The Swiss drugmaker said the investments will create 12,000 construction and other jobs.

2 months ago | wsj.com | Peter Loftus

Moderna shares fell 3% in premarket trading after the biotech company swung to a quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2.91 per share, which included costs to end a contract manufacturing deal and an inventory writedown. A year earlier, Moderna earned $217 million, or 55 cents a share.

2 months ago | wsj.com | Peter Loftus

Johnson & Johnson’s halt of U.S. sales of a new heart-rhythm device due to safety concerns is hobbling a major strategic push by the company into one of the industry’s fastest-growing markets. The healthcare company paused use of the device, known as Varipulse, last month after receiving reports of neurovascular events in several patients.